SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gliatech (GLIA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (1314)2/5/2000 7:36:00 PM
From: Torben Noerup Nielsen  Read Replies (1) of 2001
 
V1,

Getting approval for re-imbursement is going to be an increasing problem for *every* drug. You're going to have to demonstrate to the insurance company that it benefits the bottom line; i.e., that they'll at least not *increase* their costs by reimbursing for something. For ADCON, that means making the argument that there'll be fewer complications possibly requiring repeat surgery. Additionally, if there is something available that can reduce the risk of complications and an insurance company refuses to reimburse for it, they do incur liability. So does the surgeon. As to ADCON not being approved for other indications, I fully understand that. But I'm guessing that it *will* be.

In this case, I disagree with you. I'd not be happy with $16/share for the ADCON side of the business. Not unless there was a substantial long-term royalty paid as well.

However, it's all going to be up to the company. Presumably, their management has a better handle on the risks/rewards.

Thanks, Torben
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News